{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T13:16:04Z","timestamp":1672319764951},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s12325-013-0072-x","type":"journal-article","created":{"date-parts":[[2013,11,18]],"date-time":"2013-11-18T14:55:55Z","timestamp":1384786555000},"page":"1018-1029","source":"Crossref","is-referenced-by-count":10,"title":["Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"30","author":[{"given":"Jin Ah","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Ryul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Wook","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wooseong","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"key":"72_CR1","unstructured":"International Diabetes Federation: IDF Diabetes Atlas, 5th edn. [Internet]. International Diabetes Federation. Brussels, Belgium: Verf\u00fcgbar unter. 2012. http:\/\/www.idf.org\/diabetes . Accessed 06 Oct 2013."},{"key":"72_CR2","unstructured":"Centers for Disease Control and Prevention. National Diabetes Fact Sheet. 2011. Available from http:\/\/www.cdc.gov\/diabetes\/pubs\/pdf\/ndfs_2011.pdf . Accessed 06 Oct 2013."},{"key":"72_CR3","doi-asserted-by":"crossref","unstructured":"Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977\u201386.","DOI":"10.1056\/NEJM199309303291401"},{"key":"72_CR4","doi-asserted-by":"crossref","unstructured":"United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165\u201375.","DOI":"10.7326\/0003-4819-128-3-199802010-00001"},{"issue":"174","key":"72_CR5","first-page":"80","volume":"30","author":"ZT Bloomgarden","year":"2007","unstructured":"Bloomgarden ZT. Achieving glycemic goals in type 2 diabetes. Diabetes Care. 2007;30(174):80.","journal-title":"Diabetes Care"},{"issue":"1709","key":"72_CR6","first-page":"16","volume":"358","author":"A Dornhorst","year":"2001","unstructured":"Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358(1709):16.","journal-title":"Lancet"},{"issue":"812","key":"72_CR7","first-page":"21","volume":"37","author":"X Gao","year":"2009","unstructured":"Gao X, Mitiglinide Versus Nateglinide Comparison Study Group. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res. 2009;37(812):21.","journal-title":"J Int Med Res"},{"issue":"1615","key":"72_CR8","first-page":"23","volume":"44","author":"HM Phillippe","year":"2010","unstructured":"Phillippe HM, Wargo KA. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2010;44(1615):23.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"72_CR9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.107.120592","volume":"322","author":"M Shigeto","year":"2007","unstructured":"Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther. 2007;322(1):7.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2691","key":"72_CR10","first-page":"8","volume":"9","author":"WJ Malaisse","year":"2008","unstructured":"Malaisse WJ. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother. 2008;9(2691):8.","journal-title":"Expert Opin Pharmacother"},{"issue":"119","key":"72_CR11","first-page":"25","volume":"431","author":"Y Sunaga","year":"2001","unstructured":"Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001;431(119):25.","journal-title":"Eur J Pharmacol"},{"key":"72_CR12","first-page":"1951","volume":"28","author":"Y Toyoda","year":"2008","unstructured":"Toyoda Y, Mizutani K, Miwa I. Increase in hepatic glucose metabolism by mitiglinide calcium dehydrate-induced translocation of glucokinase from the nuclear to the cytoplasm. Prog Med. 2008;28:1951\u20138.","journal-title":"Prog Med"},{"issue":"557","key":"72_CR13","first-page":"68","volume":"7","author":"NA Thornberry","year":"2007","unstructured":"Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem. 2007;7(557):68.","journal-title":"Curr Top Med Chem"},{"issue":"189","key":"72_CR14","first-page":"96","volume":"73","author":"G Bock","year":"2010","unstructured":"Bock G, Dalla Man C, Micheletto F, et al. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf). 2010;73(189):96.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"31","key":"72_CR15","first-page":"41","volume":"3","author":"B Ahren","year":"2010","unstructured":"Ahren B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes. 2010;3(31):41.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"738","key":"72_CR16","first-page":"46","volume":"320","author":"K Yamazaki","year":"2007","unstructured":"Yamazaki K, Yasuda N, Inoue T, et al. Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats. J Pharmacol Exp Ther. 2007;320(738):46.","journal-title":"J Pharmacol Exp Ther"},{"key":"72_CR17","unstructured":"The World Medical Association (WMA). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available from http:\/\/www.wma.net\/en\/30publications\/10policy\/b3\/index.html . Accessed 11 Nov 2013."},{"key":"72_CR18","volume-title":"Clinical pharmacokinetics and pharmacodynamics: concept and applications","author":"M Rowland","year":"2011","unstructured":"Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concept and applications. 4th ed. Baltimore: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2011.","edition":"4"},{"key":"72_CR19","first-page":"1985","volume":"47","author":"RR Little","year":"2001","unstructured":"Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem. 2001;47:1985\u201392.","journal-title":"Clin Chem"},{"issue":"675","key":"72_CR20","first-page":"88","volume":"78","author":"GA Herman","year":"2005","unstructured":"Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(675):88.","journal-title":"Clin Pharmacol Ther"},{"issue":"1475","key":"72_CR21","first-page":"80","volume":"56","author":"A Vella","year":"2007","unstructured":"Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56(1475):80.","journal-title":"Diabetes"},{"issue":"2078","key":"72_CR22","first-page":"84","volume":"89","author":"B Ahr\u00e9n","year":"2004","unstructured":"Ahr\u00e9n B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(2078):84.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1584","key":"72_CR23","first-page":"92","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(1584):92.","journal-title":"Hepatology"},{"issue":"379","key":"72_CR24","first-page":"90","volume":"36","author":"JE Stevens","year":"2012","unstructured":"Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans\u2014a randomised, controlled study. Aliment Pharmacol Ther. 2012;36(379):90.","journal-title":"Aliment Pharmacol Ther"},{"issue":"101","key":"72_CR25","first-page":"9","volume":"4","author":"A Stonehouse","year":"2008","unstructured":"Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin-based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev. 2008;4(101):9.","journal-title":"Curr Diabetes Rev"},{"issue":"Suppl 1","key":"72_CR26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1463-1326.2011.01449.x","volume":"13","author":"D D\u2019Alession","year":"2011","unstructured":"D\u2019Alession D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab. 2011;13(Suppl 1):126\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"278","key":"72_CR27","first-page":"86","volume":"568","author":"NA Duffy","year":"2007","unstructured":"Duffy NA, Green BD, Irwin N, et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol. 2007;568(278):86.","journal-title":"Eur J Pharmacol"},{"issue":"741","key":"72_CR28","first-page":"4","volume":"36","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(741):4.","journal-title":"Diabetologia"},{"issue":"2632","key":"72_CR29","first-page":"7","volume":"29","author":"P Aschner","year":"2006","unstructured":"Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(2632):7.","journal-title":"Diabetes Care"},{"key":"72_CR30","unstructured":"Sitagliptin post-marketing surveillance study (in Japanese). MSD KK. Available at: http:\/\/www.msd.co.jp\/Documents\/hcp\/...\/eppv_midterm2_januvia_tab.pdf . Accessed 11 Nov 2013."},{"key":"72_CR31","unstructured":"Inagaki N, Iwakura T, Iwamoto Y, Kadowaki T, Seino S, Seino Y. Committee for the Proper Use of Incretin-based Therapy. Available at: http:\/\/www.nittokyo.or.jp\/kinkyu_incretin100408m.html (in Japanese). Accessed 11 Nov 2013."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-013-0072-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0072-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T07:56:04Z","timestamp":1559462164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-013-0072-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1007\/s12325-013-0072-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}